Line 171: |
Line 171: |
| *'''Famotidine''' 10-15mg/kg PO every 24 hours | | *'''Famotidine''' 10-15mg/kg PO every 24 hours |
| | | |
− | ===Proton-pump inhibitors=== | + | ===Proton-pump inhibitors (PPIs)=== |
− | This class of compounds is the newest addition to the antisecretory group. Unlike Ha-receptor antagonists, proton-pump inhibitors block the enzyme (pump) responsible for a hydrogen-potassium exchange. Blocking this enzyme exchange retards the final step in parietal cell acid production. Omeprazole, one of 2 compounds in this class currently licensed in the United States for use in man, is now licensed for use in horses. It has demonstrated an excellent efficacy and safety profile. In double-blind, placebo-controlled field trials, omeprazole paste, administered at 4 mgkg bwt was effective in eliminating or substantially reducing the severity of gastric ulcers. At this dose rate, pH >6 persisted for 24 h after the last treatment. In human medicine, omeprazole has been approved for long term and prophylactic use in patients with erosive oesophagitis. This is meaningful, because ulcers in the squamous portion of the equine stomach are most prevalent (>go%) and resemble the human form of erosive oesophagitis.(EGUC)
| + | |
| + | PPIs irreversibly bind to the H+K+-ATPase proton pump of the parietal cell and block the secretion of hydrogen ions. These agents are more effective than H2 antagonsists as their action is receptor-independent, it blocks the final pathwya of acid secretion and.(EGUC) |
| + | |
| + | Omeprazole, one of 2 compounds in this class currently licensed in the United States for use in man, is now licensed for use in horses. It has demonstrated an excellent efficacy and safety profile. In double-blind, placebo-controlled field trials, omeprazole paste, administered at 4 mgkg bwt was effective in eliminating or substantially reducing the severity of gastric ulcers. At this dose rate, pH >6 persisted for 24 h after the last treatment. In human medicine, omeprazole has been approved for long term and prophylactic use in patients with erosive oesophagitis. This is meaningful, because ulcers in the squamous portion of the equine stomach are most prevalent (>go%) and resemble the human form of erosive oesophagitis.(EGUC) |
| Treatment of uncomplicated equine peptic ulcer disease | | Treatment of uncomplicated equine peptic ulcer disease |
| Omeprazole has the advantages that: | | Omeprazole has the advantages that: |
Line 179: |
Line 182: |
| Its ease of administration and once-daily dosing promotes compliance with a recommended treatment | | Its ease of administration and once-daily dosing promotes compliance with a recommended treatment |
| strategy.(EGUC) | | strategy.(EGUC) |
− | A newer and more effective treatment approach is inhibition of the proton pump, also Proton pump inhibitors bind irreversibly to the enzyme hydrogen-potassium adenosine triphosphate (H+, K+, ATPase) needed for secretion of hydrogen ions from parietal cells into the gastric lumen. The proton pump is the final pathway in gastric acid secretion. Maximum control of acid production is achieved regardless of the stimulus to the parietal cell. One important advantage of proton pump inhibitors is their ability to inhibit acid production for 24 h with once-a-day dosing (Papich 1993). The recommended dose of oral omeprazole is 4.0 mgkg bwt every 24 h.(Orsini)
| + | . One important advantage of proton pump inhibitors is their ability to inhibit acid production for 24 h with once-a-day dosing (Papich 1993). The recommended dose of oral omeprazole is 4.0 mgkg bwt every 24 h.(Orsini) |
− | | |
| | | |
− | J Vet Intern Med. 2006 Sep-Oct;20(5):1202-6.
| |
− | Effects of intravenously administrated omeprazole on gastric juice pH and gastric ulcer scores in adult horses.
| |
− | Andrews FM, Frank N, Sommardahl CS, Buchanan BR, Elliott SB, Allen VA.
| |
− | The study was performed to evaluate the efficacy of omeprazole powder in sterile water, administered intravenously, on gastric juice pH in adult horses with naturally occurring gastric ulcers. Because of its potent and long duration of action on gastric juice pH, this intravenous formulation of omeprazole may show promise for treatment of equine gastric ulcer syndrome (EGUS) in horses with dysphagia, gastric reflux, or other conditions that restrict oral intake of omeprazole paste. Aspiration of gastric juice and measurement of pH can be of use to determine whether the desired pH > 4.0 has been reached after omeprazole treatment.
| |
| | | |
| Omeprazole, a substituted benzimidazole Omeprazole inhibits H+K+ATPase, the enzyme responsible for the final production of acid by parietal cells. In man, it has recently been shown that healing of erosive oesophagitis with antisecretory drugs is directly correlated to both the duration of acid suppression over a 24 h period and the elevation of intraoesophageal pH above 4 for at least 96% of the 24 h period (Tibbling 1993). In horses, orally administered omeprazole has been shown to increase stomach pH above 4 and to significantly inhibit gastric secretion for at least 27 h after treatment (Bough et al. 1995) In addition, omeprazole has a longer duration of action than the H2 receptor antagonists and, consequently, only requires once daily dosing (Brown and Rees 1994). No side-effects were observed in any of the horses in our study. Similarly, in 2 studies in which omeprazole was administered orally to horses over a 5 day period no adverse effects were noted (Ryberg et al. 1989; Bough et al. 1995). At the present dosage, omeprazole appears safe for use in horses, although further studies are required. As with human individuals suffering GERD (Gunasekaran and Hassall 1993), once omeprazole treatment was stopped in the horses, ulceration returned within 2 weeks. Presumably the same factors responsible for the development of ulcers in horses were still present at the end of the trial. In man, long-term treatment of GERD has been achieved by placing patents on a maintenance dose of omeprazole (Gunasekaran and Hassall 1993). Although no side-effects were observed in human patients receiving long-term omeprazole therapy (Goldberg | | Omeprazole, a substituted benzimidazole Omeprazole inhibits H+K+ATPase, the enzyme responsible for the final production of acid by parietal cells. In man, it has recently been shown that healing of erosive oesophagitis with antisecretory drugs is directly correlated to both the duration of acid suppression over a 24 h period and the elevation of intraoesophageal pH above 4 for at least 96% of the 24 h period (Tibbling 1993). In horses, orally administered omeprazole has been shown to increase stomach pH above 4 and to significantly inhibit gastric secretion for at least 27 h after treatment (Bough et al. 1995) In addition, omeprazole has a longer duration of action than the H2 receptor antagonists and, consequently, only requires once daily dosing (Brown and Rees 1994). No side-effects were observed in any of the horses in our study. Similarly, in 2 studies in which omeprazole was administered orally to horses over a 5 day period no adverse effects were noted (Ryberg et al. 1989; Bough et al. 1995). At the present dosage, omeprazole appears safe for use in horses, although further studies are required. As with human individuals suffering GERD (Gunasekaran and Hassall 1993), once omeprazole treatment was stopped in the horses, ulceration returned within 2 weeks. Presumably the same factors responsible for the development of ulcers in horses were still present at the end of the trial. In man, long-term treatment of GERD has been achieved by placing patents on a maintenance dose of omeprazole (Gunasekaran and Hassall 1993). Although no side-effects were observed in human patients receiving long-term omeprazole therapy (Goldberg |
Line 195: |
Line 193: |
| Javsicas LH, Sanchez LC. | | Javsicas LH, Sanchez LC. |
| Omeprazole paste effectively increases intragastric pH in clinically ill neonatal foals after one dose at 4 mg/kg bwt orally. | | Omeprazole paste effectively increases intragastric pH in clinically ill neonatal foals after one dose at 4 mg/kg bwt orally. |
− |
| |
| | | |
| ===Antacids=== | | ===Antacids=== |